# A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

> **NCT03880019** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 23 (actual)

## Conditions studied

- Stage III Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
- Uterine Corpus Leiomyosarcoma

## Interventions

- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Core Biopsy
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Olaparib
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT03880019
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-19
- **Primary completion:** 2020-08-01
- **Final completion:** 2026-11-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03880019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03880019, "A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03880019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*